Frederick Sanger and his Cambridge colleagues read insulin's building-block order and mapped the links joining its two chains. Completed in 1955, the Frederick Sanger insulin sequence work made insulin the first fully sequenced protein, a molecule made from amino acids, or chemical building blocks.
A sequence is the order of those blocks. Insulin was already a medicine.
The Frederick Sanger insulin sequence problem
At Cambridge, Sanger began studying protein structure in 1943, according to his Nobel biography. Insulin is a chemical messenger that helps control blood sugar.
Researchers could measure its ingredients. The hard part was reading their order. Sanger used cattle insulin, which had relatively short chains and was already well studied.
The finding: two chains and three bridges
Insulin contains 51 amino acids: 21 in its A chain and 30 in its B chain. The MRC Laboratory of Molecular Biology's account describes Sanger's mapping of the order and links. Disulfide bonds are chemical bridges formed through sulfur in certain amino acids. Two join insulin's chains; a third connects two points within the A chain.
The papers show who sequenced insulin
Researchers marked chain ends, cut the chains into pieces and matched overlapping stretches. The Biochemical Journal papers record the steps:
- 1951: Sanger and Hans Tuppy reported the B-chain sequence.
- 1953: Sanger and E. O. P. Thompson published work on the A chain.
- 1955: A. P. Ryle, Sanger, L. F. Smith and Ruth Kitai reported the disulfide bonds.
Those checks revealed a definite order. The 1955 paper added the bridge positions.
Frederick Sanger's 1958 chemistry Nobel
Sanger was the sole recipient of the 1958 Nobel Prize in Chemistry for his work on protein structure, especially insulin. The papers credit his collaborators.
This was a separate achievement from the 1923 Nobel Prize for discovering insulin.
Why exact sequence matters for semaglutide
Modern peptide medicines make the importance of that order easier to see. A peptide is a chain of amino acids; semaglutide is a modified version of GLP-1, a chemical messenger released by the gut.
In their 2015 discovery paper in the Journal of Medicinal Chemistry, Jesper Lau and colleagues described two amino-acid substitutions, meaning building-block replacements. They also attached a fatty acid, a component of fat, as a chemical tail.
Those choices helped protect the molecule from breakdown and support binding to albumin, a protein in blood. Semaglutide's identity includes those changes. Calling it a peptide alone leaves out much of what distinguishes it.
What came after the insulin sequence
Reading an order and seeing a shape remained different jobs. Dorothy Hodgkin's team mapped insulin's three-dimensional structure in 1969. Their work asked how the parts fitted together in space.
Sanger also moved into reading RNA and DNA, molecules that carry genetic information. His Nobel biography describes that later work and his second chemistry prize in 1980.
DNA stores biological instructions in a different chemical alphabet. Reading that alphabet wasn't the same task as taking a protein apart. The shared idea was that the exact order could be determined experimentally.
As of November 12, 2026, the day this article was written, an August 26, 2026 study in Science Advances reports another way GLP-1 is broken down. Lu Zhang and colleagues traced this breakdown to insulin-degrading enzyme, or IDE, a protein that cuts peptide chains. Changing particular building blocks in GLP-1 and semaglutide helped the experimental molecules resist those cuts. These laboratory and mouse findings leave human benefits and harms as separate questions.
Tirzepatide: a different chain with two receiving sites
Tirzepatide illustrates another reason exact identity matters. It has 39 amino acids and a fatty-acid attachment. Its development code was LY3298176.
Tamer Coskun and colleagues described its design in a 2018 Molecular Metabolism discovery paper. It acts at receptors, the receiving sites on cells, for both GLP-1 and GIP. GIP is another chemical messenger from the gut, involved in insulin release.
That is one chain acting through two receiving sites. Tirzepatide isn't insulin, and it isn't a mixture of insulin and semaglutide. It helps signal insulin release rather than supplying insulin itself.
The link to Sanger is the need to identify a molecule precisely. His insulin experiments didn't test tirzepatide or establish its treatment outcomes.
What knowing a sequence leaves unanswered
A sequence identifies the order of the parts. It doesn't explain every detail of their shape, how a medicine behaves in a person or its unwanted effects.
Sanger made that limit clear in his December 11, 1958 Nobel lecture. Even after mapping insulin, researchers still had questions about how its chemistry related to its action.
His lecture compared insulin from different animal species, where some building blocks differed. A result from cattle insulin didn't automatically describe every other insulin. That is a useful question when reading any study: which molecule was tested, in what setting, and what did the researchers actually measure?
The same distinction matters today. Knowing a peptide's structure can guide experiments. Patient benefits and harms need their own evidence. A famous place in insulin's history doesn't give a later molecule the same evidence.
For prescribed semaglutide, the preparation matters too
Knowing semaglutide's sequence doesn't establish the quality of every preparation bearing its name. The identity of an ingredient and the review of a finished medication are separate questions.
The discovery papers describe particular molecules and experiments. They do not test every later pharmacy preparation. A familiar ingredient name doesn't make the contents, handling or evidence of all preparations identical.
Compounding means a pharmacy prepares or changes a medication for a patient's needs.
As of November 12, 2026, the day this article was written, FDA explains that compounded drugs do not undergo its premarket safety, effectiveness or quality review. That page is marked “Content current as of: 09/16/2025.”
Semaglutide and tirzepatide prescribed through Promise are dispensed by a licensed U.S. compounding pharmacy as compounded medications. They are different from FDA-approved products: the formulations offered here are not FDA-approved.
A licensed provider may still prescribe — that decision is between you and your doctor.
Where the history meets a visit
At Promise, a licensed provider reviews every request, and not everyone qualifies. The review considers medical history, current medicines, the reason for treatment and follow-up.
For example, a request for semaglutide involves the person's current medicines and the intended use. The provider needs information about the person as well as the molecule. A sequence cannot show whether two prescriptions might interact or whether a change during treatment needs attention.
The clinical conversation adds the questions a chemical map cannot answer: what evidence fits this person's situation, and how will treatment be monitored?





